

\$104.88 **\$0.59 (0.57%)** as of Friday's close

Cap (\$M USD)
\$182,077

P/E
35.7

EPS (1Y)
-33.6%

Dividend
\$2.04

Last Filing
09/30/23

52-wk Range

\$89.67  \$115.83

Sales (\$M)
39,959

Forward P/E
22.7

Sales (1Y)
-11.3%

Div. Yield
2.0%

Next Earnings
01/24/24

Dividend Adjusted Return Dec 1, 2022 - Dec 1, 2023



ABT has underperformed the S&P 500 by -15.0% in the past year.



ABT has outperformed its sector by 3.6% in the past year.

The Healthcare sector has underperformed the market by -18.6% in the past year.

ANALYST CONSENSUS

Buy

The consensus rating is unchanged from 1 month ago.



QUANTITATIVE SCORES

Fair Value \$99.14

Margin of Safety -5%

The Margin of Safety is the difference between a company's Fair Value and the current price. See more on page 8.

3 warnings
Details on Page 8

Value Score

71

Value Score: Our value score looks at EV/EBITDA, P/E, P/S, P/TB (Price/Tangible Book) and EPS Predictability. P/S and P/TB are compared within a sector. Other metrics are compared across all stocks

Quality Score

91

Quality Score: Our quality score compares profitability and balance sheet metrics to find high quality companies using ROIC, Net Margin, Gross Margin, Interest Coverage, and Debt / Equity metrics.

Growth Score

65

Growth Score: Our growth score looks at the 5 year history and the forward estimates for EBITDA, Sales, and EPS growth, ranking the best companies across all stocks.

Sentiment Score

88

Sentiment Score: Our sentiment score finds stocks in favor by analyzing Short Interest, returns in key periods over the last year, Price vs. 52-wk High, Days Since 52-wk High and MACD signals.

BUSINESS SUMMARY

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees 115,000

Homepage www.abbottinvestor.com

Headquarters Abbott Park, IL


VALUATION SUMMARY

	ABT	Industry	S&P 500
Value Score	71	41	72
Price / Earnings	35.7	73.1	25.7
Price / Sales	4.6	3.8	2.6
Price / Free Cash Flow	40.8	63.7	25.6
Price / Book	4.9	3.6	4.5
Price / Tangible Book	37.0	97.9	500+
EV / EBITDA	18.9	19.7	21.6
EPS Predict. Pctl.	69	57	68
Piotroski F Score	5	3	5
5-Year P/E Range	19.8		178.5
5-Year P/B Range	3.5		7.4
5-Year P/S Range	3.6		7.1



GROWTH SUMMARY

	ABT	Industry	S&P 500
Growth Score	65	50	74
Sales Growth			
Sales Growth Next Year	4.0%	5.3%	8.9%
Sales 1-Year Chg (%)	-11.3%	0.7%	11.6%
Sales 3-Year Avg (%)	7.4%	8.7%	13.0%
Sales 5-Year Avg (%)	5.6%	2.4%	12.4%
EPS Growth			
Next Yr. Growth Est.	4.1%	9.9%	14.0%
EPS 1-Year Chg (%)	-33.6%	-	8.1%
EPS 3-Year Avg (%)	16.1%	-15.8%	22.0%
EPS 5-Year Avg (%)	45.5%	5.5%	11.8%




PEERS ANALYSIS SUMMARY

Ticker	Company	Cap (\$M USD)	P/E	Div. Yield	1M Return	1Y Return	Margin of Safety	Value Score	Growth Score	Quality Score
ABT	Abbott Laboratories	\$182,077	35.7	2.0%	10.4%	-0.9%	-5%	71	65	91
SYK	Stryker	\$113,128	44.3	1.0%	9.5%	25.1%	-1%	70	91	63
MDT	Medtronic	\$106,359	26.0	3.5%	12.9%	4.4%	-4%	77	72	85
BSX	Boston Scientific	\$82,244	68.5	-	8.7%	21.7%	-1%	56	92	82
DXCM	DexCom	\$44,510	128.2	-	23.9%	-1.2%	-22%	57	98	85
EW	Edwards Lifescien...	\$41,460	29.2	-	7.1%	-11.9%	2%	72	86	86
ZBH	Zimmer Biomet Ho...	\$24,653	52.1	0.8%	12.3%	-3.6%	23%	65	76	77
STE	Steris	\$20,106	36.9	1.0%	-4.2%	6.9%	3%	70	77	80
PHG	Koninklijke Philips	\$18,715	-	-	5.6%	43.1%	-	63	43	55
ALGN	Align Tech	\$16,877	46.7	-	20.3%	9.2%	22%	77	72	75
PODD	Insulet	\$13,413	111.1	-	39.5%	-37.6%	-	54	99	76
SNN	Smith & Nephew	\$11,211	52.6	2.8%	18.2%	1.7%	19%	49	71	73

PROFITABILITY SUMMARY

	ABT	Industry	S&P 500
Quality Score	91	47	77
Gross Margin	54.9%	56.4%	29.6%
Operating Margin	15.0%	10.5%	14.2%
Net Margin	12.9%	5.5%	10.4%
Return on Assets	7.0%	5.6%	9.2%
Return on Equity	13.8%	10.8%	32.6%
ROIC	10.9%	6.6%	20.8%



RETURNS SUMMARY

	ABT	Industry	S&P 500
Sentiment Score	88	51	74
5-Day Return	2.0%	1.9%	0.8%
1-Month Return	10.4%	12.1%	8.4%
YTD Return	-2.6%	3.3%	21.0%
1-Year Return	-0.9%	1.9%	14.5%
3-Year Return	1.8%	-12.0%	31.2%
5-Year Return	54.0%	23.7%	81.0%
Beta 1-Year	0.64	0.72	0.99




DIVIDEND

	ABT	Industry
Dividend Yield	2.0%	1.2%
Payout Ratio	67.8%	57.6%
TTM Yield	2.0%	-
Dividend Per Share	\$2.04	\$1.32
Div. 1Y Chg (%)	8.5%	16.5%
Div. 3Y Avg (%)	12.3%	16.5%
Div. 5Y Avg (%)	12.7%	16.5%
Cons. Growth Years	9	3
Div. Coverage Ratio	1.5	1.7

DEBT & EQUITY

Current Ratio	1.7
Quick Ratio	1.2
Price	\$104.88
Net Cash Per Share	-\$4.89
Equity Per Share	\$21.59
Debt / Equity	0.4
Solvency Ratio	31%
Interest Coverage	10.8
Short % of Float	0.7%
Altman Z-Score	4.9



ANALYST REVISIONS

Current Quarter EPS		Next Quarter EPS	
# Up Last 30 days	0.00	# Up Last 30 days	0.00
# Down Last 30 days	0.00	# Down Last 30 days	0.00
Mean Estimate	1.04	Mean Estimate	1.19
% Change (30 Days)	-	% Change (30 Days)	-

MEAN ESTIMATE TREND

	Cur Qtr	Next Qtr	Cur Year	Next Year
Latest	\$1.19	\$1.04	\$4.44	\$4.62
30 Days Ago	\$1.19	\$1.04	\$4.44	\$4.62
90 Days Ago	\$1.19	\$1.05	\$4.40	\$4.62
% Change (90 Days)	0.0%	-1.0%	0.9%	0.0%

EARNINGS SURPRISES

Earnings surprise is the difference between a company's announced earnings and the average analyst estimated value. Surprises typically causes the stock price to jump and are often followed by more of the same surprise type.

Surprise Detail (Last 6 Quarters)

Surprise Summary (Last 12 Quarters)


Surprise Type	Amount	Percent
Positive Quarters (> 2%)	12	100.0%
Negative Quarters (< 2%)	0	-
In-Line Quarters (within 2%)	0	-

Surprise Type	Announce Date	Period End Date	Actual EPS	Est. EPS	Surprise (%)
Positive	10/18/23	09/30/23	\$1.14	\$1.10	3.6%
Positive	07/20/23	06/30/23	\$1.08	\$1.05	2.9%
Positive	04/19/23	03/31/23	\$0.94	\$0.90	4.4%
Positive	01/25/23	12/31/22	\$1.03	\$0.92	12.0%
Positive	10/19/22	09/30/22	\$1.15	\$0.94	22.3%
Positive	07/20/22	-	\$1.43	\$1.13	26.5%

RISK


	ABT	Industry	S&P 500
Best Monthly Return (5Y)	20.3%	18.7%	17.9%
Worst Monthly Return (5Y)	-11.5%	-11.2%	-16.4%
Beta 1-Year	0.64	0.72	0.99
Volatility 1-Year	0.20	0.15	0.13
Volatility 1Y Pctl.	19	-	-
Max Drawdown 1-Year	-21.3%	-27.4%	-10.3%
Max Drawdown 3-Year	-36.2%	-45.6%	-25.4%
Max Drawdown 5-Year	-36.2%	-49.0%	-33.9%

ABT Volatility 1-Year 0.2



SEASONALITY

Seasonal Performance vs the S&P 500



5-YEAR RELATIVE PERFORMANCE VS S&P 500

Relative to the S&P 500 baseline, ABT has underperformed the S&P 500 by -26.8% in the past 5 Years.

ABT has outperformed its sector by 8.3% in the past 5 Years.

The Healthcare sector has underperformed the market by -35.2% in the past 5 Years.

Dividend Adjusted Return Nov 30, 2018 - Dec 1, 2023



Overall Rating vs. Peers

71

Ratings scores are relative to industry groups. They compare key metrics to rank stocks vs. their competitors. For example, higher growth than peers will score high even when the absolute growth is below the market average.

Growth vs Peers								
Ticker	Company	Growth Rating vs. Peer	Sales QoQ Chg.	Eps QoQ Chg.	Sales Growth Next Y.	Sales 1Y Chg (%)	Sales 3Y Avg (%)	Sales 5Y Avg (%)
DXCM	DexCom	99	26.7%	20.8%	20.3%	21.8%	23.2%	30.0%
BSX	Boston Scientific	87	11.3%	183.3%	8.5%	9.5%	10.8%	7.3%
EW	Edwards Lifesciences	77	12.3%	14.6%	9.2%	8.5%	10.0%	9.9%
MDT	Medtronic	47	5.3%	112.5%	4.4%	3.7%	4.7%	1.0%
ABT	Abbott Laboratories	37	-2.6%	1.2%	4.0%	-11.3%	7.4%	5.6%

Valuation vs Peers								
Ticker	Company	Valuation Rating vs. Peer	P/E	Forward P/E	PEG Trailing	P/S	P/B	5Y P/E Range
MDT	Medtronic	91	26.0	14.7	2.0	3.3	2.1	19.7 - 61.8
ABT	Abbott Laboratories	67	35.7	22.7	0.8	4.6	4.9	19.8 - 178.5
EW	Edwards Lifesciences	65	29.2	24.3	1.8	7.2	6.2	26.4 - 91.2
BSX	Boston Scientific	52	68.5	25.1	6.1	5.9	4.4	9.1 - -
DXCM	DexCom	7	128.2	68.6	2.6	14.7	19.6	63.9 - -


Efficiency vs Peers								
Ticker	Company	Efficiency Rating vs. Peer	Gross Margin	Operating Margin	Net Margin	5Y ROE Range		5Y ROA Range
EW	Edwards Lifescie...	99	78.0%	30.1%	24.6%	18.0%	28.5%	12.0% - 21.2%
DXCM	DexCom	94	63.9%	14.9%	11.1%	-22.4%	27.0%	-10.2% - 14.8%
ABT	Abbott Laboratories	93	54.9%	15.0%	12.9%	7.8%	23.4%	3.3% - 11.6%
MDT	Medtronic	81	65.4%	19.0%	12.8%	4.6%	10.3%	2.4% - 5.9%
BSX	Boston Scientific	80	69.1%	16.9%	8.9%	-0.8%	33.9%	-0.4% - 18.2%

Financial Strength vs Peers								
Ticker	Company	Financial Str. Rating vs. Peers	Debt / Equity	Interest Coverage	Quick Ratio	Intangibles %	Solvency Ratio	Short % of Float
BSX	Boston Scientific	88	0.5	8.1	0.9	57.2%	18%	0.8%
MDT	Medtronic	81	0.5	9.0	1.7	60.9%	20%	0.7%
ABT	Abbott Laboratories	80	0.4	10.8	1.2	45.2%	31%	0.7%
EW	Edwards Lifesciences	76	0.1	-	2.5	18.4%	83%	1.8%
DXCM	DexCom	72	1.2	30.7	2.5	2.6%	13%	5.3%

Dividends vs Peers								
Ticker	Company	Dividends Rating vs. Peer	Div. Yield	TTM Yield	Price	Div. Per Share	Consecutive Div. Growth Years	Payout Ratio
MDT	Medtronic	91	3.5%	3.4%	\$79.99	\$2.76	9	88.7%
ABT	Abbott Laboratories	36	2.0%	2.0%	\$104.88	\$2.04	9	67.8%
BSX	Boston Scientific	-	-	-	\$56.14	-	0	-
DXCM	DexCom	-	-	-	\$116.62	-	0	-
EW	Edwards Lifesciences	-	-	-	\$68.36	-	0	-

Momentum vs Peers										
Ticker	Company	Momentum Rating vs. Peer	1M Return	3M Return	6M Return	YTD Return	1Y Return	Beta 1Y	Volatility 1Y	Price vs 52-wk High (%)
DXCM	DexCom	65	23.9%	14.5%	-2.5%	3.0%	-1.2%	0.89	0.40	83.6%
BSX	Boston Scientific	64	8.7%	4.7%	9.0%	21.3%	21.7%	0.55	0.20	99.9%
ABT	Abbott Laboratories	51	10.4%	2.5%	3.1%	-2.6%	-0.9%	0.64	0.20	90.6%
MDT	Medtronic	47	12.9%	-1.8%	-1.7%	5.5%	4.4%	0.64	0.21	86.9%
EW	Edwards Lifesciences	19	7.1%	-10.5%	-19.8%	-8.4%	-11.9%	1.05	0.27	72.1%

DIVIDEND DETAIL



CALENDAR YEAR DIVIDEND HISTORY

Year	Ex-Dividend	Pay Date	Text	Amount
2023 Dividends				\$2.04
	10/12/23	11/15/23	Regular	\$0.51
	07/13/23	08/15/23	Regular	\$0.51
	04/13/23	05/15/23	Regular	\$0.51
	01/12/23	02/15/23	Regular	\$0.51
2022 Dividends				\$1.88
	10/13/22	11/15/22	Regular	\$0.47
	07/14/22	08/15/22	Regular	\$0.47
	04/13/22	05/16/22	Regular	\$0.47
	01/13/22	02/15/22	Regular	\$0.47
2021 Dividends				\$1.80
	10/14/21	11/15/21	Regular	\$0.45
	07/14/21	08/16/21	Regular	\$0.45
	04/14/21	05/17/21	Regular	\$0.45
	01/14/21	02/16/21	Regular	\$0.45
2020 Dividends				\$1.44
	10/14/20	11/16/20	Regular	\$0.36
	07/14/20	08/17/20	Regular	\$0.36
	04/14/20	05/15/20	Regular	\$0.36
	01/14/20	02/14/20	Regular	\$0.36
2019 Dividends				\$1.28
	10/11/19	11/15/19	Regular	\$0.32
	07/12/19	08/15/19	Regular	\$0.32
	04/12/19	05/15/19	Regular	\$0.32

UPCOMING DIVIDEND

Ex-Dividend Date	10/12/23
Payment Date	11/15/23
Amount	\$0.51
Type	Regular

DIVIDEND RATE

Regular Dividend	\$0.51
Annual Dividend Rate	\$2.04
Annual Dividend Yield	1.9%
Trailing 12 Months Dividends	\$2.04
Trailing 12 Months Yield	2.0%

STATISTICS

Payout Ratio	67.8%
Dividend Coverage Ratio	147.5%
Consecutive Growth Years	9
3 Year Growth Rate	12.3%
5 Year Growth Rate	12.7%
10 Year Growth Rate	13.8%




FINANCIAL STATEMENT SUMMARY

USD in Millions	Chart	2018	2019	2020	2021	2022	TTM	CAGR
Income Statement								
Revenue		30,578	31,904	34,608	43,075	43,653	39,959	5.6%
Operating Income		3,650	4,532	5,357	8,425	8,362	6,002	10.6%
Net income		2,368	3,687	4,495	7,071	6,933	5,162	17.2%
Earnings per share diluted		\$1.31	\$2.06	\$2.49	\$3.94	\$3.91	\$2.94	17.9%
Average shares diluted		1,770	1,781	1,786	1,789	1,764	1,751	-0.2%
P/E Ratio		161.3	47.2	58.1	35.0	24.8	35.7	-26.4%
Balance Sheet								
Cash		4,086	4,140	7,148	10,249	10,170	7,047	11.7%
Current assets		14,632	15,667	20,441	24,239	25,224	22,664	9.3%
Net Property, Plant and Equipm...		7,563	8,038	9,029	8,959	9,162	9,552	4.9%
Working Capital		5,620	4,804	8,534	11,134	9,735	9,622	11.6%
Net Debt		15,480	14,754	12,501	8,757	7,546	8,481	-11.5%
Stockholders' Equity		30,524	31,088	32,784	35,802	36,686	37,481	4.3%
Cash Flow								
Operating Cash Flow		6,300	6,136	7,901	10,533	9,581	6,549	0.8%
Cap Ex		-1,394	-1,638	-2,177	-1,885	-1,777	-2,057	8.2%
Free Cash Flow		4,906	4,498	5,724	8,648	7,804	4,492	-1.8%
Free Cash Flow per share		\$2.77	\$2.53	\$3.20	\$4.83	\$4.42	\$2.57	-1.6%
Profitability								
Operating Margin		11.9%	14.2%	15.5%	19.6%	19.2%	15.0%	4.8%
Return on Assets		3.3%	5.5%	6.4%	9.6%	9.3%	7.0%	16.6%
Return on Equity		7.8%	11.9%	13.7%	19.8%	18.9%	13.8%	12.4%
Return on Invested Capital		5.4%	8.4%	9.7%	14.0%	13.3%	10.9%	15.3%
Dividends								
Dividends Per Share		\$1.12	\$1.28	\$1.44	\$1.80	\$1.88	\$2.04	13.0%
Dividend Yield		1.8%	1.7%	1.6%	1.3%	1.9%	1.9%	1.9%
Dividend Growth		-	14.3%	12.5%	25.0%	4.4%	9.7%	-9.5%
Dividend Coverage		1.2x	1.6x	1.8x	2.2x	2.1x	1.5x	4.3%

VALUATION & PROFITABILITY HISTORY

Date →	TTM	1 Yr Ago	2 Yrs. Ago	3 Yrs. Ago	4 Yrs. Ago
Price / Earnings	35.7	22.5	35.6	63.1	52.6
Price / Cash Flow	28.0	18.8	21.4	30.2	26.5
Price / Book	4.9	5.2	6.6	6.3	4.8
Price / Tangible B...	37.0	87.4	-	-	-
Price / Sales	4.6	4.2	5.6	6.2	4.9
EV / EBITDA	18.9	14.8	18.9	27.2	22.3
Dividend Yield	2.0%	1.7%	1.4%	1.3%	1.5%
Shareholder Yield	2.9%	3.9%	2.1%	1.7%	1.7%
Gross Margin	54.9%	57.1%	56.8%	56.7%	58.6%
Net Margin	12.9%	17.5%	17.1%	10.5%	10.5%
Return on Assets	7.0%	10.7%	10.1%	5.0%	4.8%
Return on Equity	13.8%	22.1%	21.0%	10.8%	10.4%
ROIC	10.9%	16.2%	14.7%	7.9%	7.8%

WARNINGS

Name	Severity	Details
High Goodwill	Low 	Goodwill %: 32.3%
<p>Goodwill on a company's balance often results from over-paying to acquire other firms. A high percentage here can turn into impairment charges that weigh down future earnings for the company.</p>		
GAAP Earnings vs. Pro Forma	Low 	Official EPS: \$0.82; Announced EPS: \$1.14
<p>The GAAP compliant earnings that the company filed with the SEC are less than the pro-forma earnings they announced to the press. Pro-forma earnings can exclude special one-time charges but some distressed companies post these "one-time" charges quarter after quarter.</p>		
Declining EPS Growth	Low 	EPS 1Y Chg (%): -33.6%; EPS 3Y Avg (%): 16.1%; EPS 5Y Avg (%): 45.5%
<p>EPS growth has declined. Comparing EPS growth rates, the 1-year is less than the 3-year which is less than the 5-year. Be sure to understand the reasons as declining earnings growth puts pressure on the stock price.</p>		

REPORT TIPS

Metric Definitions

Metric descriptions are available at stockrover.com/help/metrics/metric-overview

Quantitative Scores

Our scores analytics is to offer our concise analysis of a stock in powerful, but easy to digest format. Each of the composite score metrics are designed to use the best available accounting practices as well as source data from SEC filings. The scores are computed for a company vs. the market as a whole.

Fair Value

Fair value performs a forecasted discounted cash flow analysis of a company to determine the company's intrinsic value based on the expected future cash flows the company will produce. It basically determines what a company is worth based on how much cash flow it is expected to generate for you in the future, taking into account the time value of money and the predictability of those forecasted cash flows.

Peers

Peer ratings are computed from raking companies in the same

DISCLAIMER

Financial Statements and Historical Prices Provided by Morningstar. © 2023 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Stock Rover and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely.

The information provided does not constitute investment advice, nor does it constitute a recommendation to buy or sell any security. Stock Rover LLC and its content providers are not responsible for any losses resulting from trading decisions arising from any use of this information. Past performance is no guarantee of future results.

The information provided is as of the date written and is subject to change without notice

Additional data provided by [Zacks](#), [Intrinio](#), [Quandl](#), [Yodlee](#), [IEX Cloud](#)